Emeriti Pharma

EP0003 - a novel mechanism

for treatment of

dermatological disorders

The plasminogen/plasmin system appears to be overactive in several dermatological conditions. By inhibiting the conversion of plasminogen to plasmin EP0003 can have beneficial effects on several skin diseases, offering new treatment opportunities.

EP0003 is formulated as a cream for topical application and a Phase I study in rosacea is ongoing.

We also plan to perform exploratory clinical studies in plaque psoriasis and melasma.














Phase I

Copyright © All Rights Reserved